Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Современные возможности эффективной терапии акне: место изотретиноина
Современные возможности эффективной терапии акне: место изотретиноина
Масюкова С.А. Современные возможности эффективной терапии акне: место изотретиноина. Consilium Medicum. Дерматология (Прил.). 2015; 4: 17–20.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
В статье представлены современные данные по эпидемиологии, патогенезу, клинической картине акне, а также изучению эффективности лечения стандартными и низкими дозами изотретиноина.
Ключевые слова: акне, изотретиноин, Сотрет, эффективность.
Key words: acne, isotretinoin, Sotret, efficiency.
Ключевые слова: акне, изотретиноин, Сотрет, эффективность.
________________________________________________
Key words: acne, isotretinoin, Sotret, efficiency.
Полный текст
Список литературы
1. Перламутров Ю.Н., Ольховская К.Б. Современные аспекты эффективной терапии acne vulgaris. Рос. журн. кожных и венерических болезней. 2014; 5. / Perlamutrov Iu.N., Ol'khovskaia K.B. Sovremennye aspekty effektivnoi terapii acne vulgaris. Ros. zhurn. kozhnykh i venericheskikh boleznei. 2014; 5. [in Russian]
2. Zouboulis CC, Piquero-Martin J. Update and future of systemic acne treatment. Dermatology 2003; 206 (1): 37–53.
3. Thiboutot D, Gollnick H, Bettoli V et al. Global Alliance to Improve Outcomes in Acne. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol 2009; 60 (Suppl. 5): S1–50. doi: 10.1016/j. jaad.2009.01.019.
4. Gollnick H, Cunliffe W, Berson D et al. Global Alliance to Improve Outcomes in Acne. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2003; 49 (Suppl. 1): S1–37.
5. Перламутров Ю.Н., Ольховская К.Б. Клинико-психологические отклонения у больных акне и методы их коррекции. Клин. дерматология и венерология. 2012; 4: 70–2. / Perlamutrov Yu.N., Olkhovskaya K.B. Clinical psychological abnormalities in patients with acne and methods of their correction. Klin. dermatologiya i venerologiya. 2012; 4: 70–2. [in Russian]
6. Dreno B, Alirezai M, Auffret N et al. Clinical and psychological correlation in acne: use of the ECLA and CADI scales. Ann Dermatol Venereol 2007; 134 (5): 451–5.
7. Котова Н.В., Суворова К.Н. Юношеские акне. М.–Новосибирск, 2002; с. 3–54. / Kotova N.V., Suvorova K.N. Iunosheskie akne. M.–Novosibirsk, 2002; s. 3–54. [in Russian]
8. Аравийская Е.Р. Современный взгляд на лечение акне: состояние проблемы и новые возможности. Леч. врач. 2003; 3: 4–6. / Araviiskaia E.R. Sovremennyi vzgliad na lechenie akne: sostoianie problemy i novye vozmozhnosti. Lech. vrach. 2003; 3: 4–6. [in Russian]
9. Cunliffe WJ. Management and differential of diagnosis acne. Berlin, 2001; 8–16.
10. Layton AM, Dreno B, Gollnick HP, Zouboulis CC. A review of the European Directive for prescribing systemic isotretinoin for acne vulgaris. J Eur Acad Dermatol Venereol 2006; 20 (7): 773–6.
11. Heller EH, Shiffman NJ. Syntheticretinoids in dermatology. Can Med Ass J 1985; 132: 10: 1129–36.
12. Goldsmith LA, Bolognia JL, Callen JP et al. American Academy of Dermatology Consensus Conference on the safe and optimal use of isotretinoin: summary and recommendations. J Am Acad Dermatol 2004; 50 (6): 900–6.
13. Hansen SR, Mikkelsen CS, Kroon S. Systemic treatment of acne. Tidsskr Nor Laegeforen 2011; 131 (2): 133–5.
14. Адаскевич В.П. Акне вульгарные и розовые. М: Медицинская книга – Н.Новгород: НГМА, 2005. / Adaskevich V.P. Akne vul'garnye i rozovye. M: Meditsinskaia kniga – N.Novgorod: NGMA, 2005. [in Russian]
15. Аравийская Е.А. Современный взгляд на лечение акне: состояние проблемы и новые возможности. Леч. врач. 2003; 4: 20–5. / Araviiskaia E.A. Sovremennyi vzgliad na lechenie akne: sostoianie problemy i novye vozmozhnosti. Lech. vrach. 2003; 4: 20–5. [in Russian]
16. Масюкова С.А., Ахтямов С.Н. Акне: проблема и решение. Concilium Medicum. Дерматология (Прил.). 2002; 5: 217–23. / Masiukova S.A., Akhtiamov S.N. Akne: problema i reshenie. Concilium Medicum. Dermatology (Suppl.). 2002; 5: 217–23. [in Russian]
17. Потекаев Н.Н., Горячкина М.В., Белоусова Т.Л. Акне (угревая болезнь): современный взгляд на проблему. Concilium Medicum. Дерматология (Прил.). 2008; 1: 12–6. / Potekaev N.N., Goriachkina M.V., Belousova T.L. Akne (ugrevaia bolezn'): sovremennyi vzgliad na problemu. Concilium Medicum. Dermatology (Suppl.). 2008; 1: 12–6. [in Russian]
18. Sardana K, Garg VK. Efficacy of low-dose isotretinoin in acne vulgaris. Indian J Dermatol Venereol Leprol 2010; 76 (1): 7–13.
19. Simpson RC, Grindlay DJ, Williams HC. What’s new in acne? An analysis of systematic reviews and clinically significant trials published in 2010–2011. Clin Exp Dermatol 2011; 36 (8): 840–3.
20. Zouboulis CC. Isotretinoinrevisited: pluripotent effects on human sebaceous gland cells. J Invest Dermatol 2006; 126 (10): 2154–6.
21. Ayer J, Burrows N. Acne: more than skin deep. Postgrad Med J 2006; 82 (970): 500–6.
22. Nelson AM, Zhao W, Gilliland KL et al. Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol 2009; 1 (3): 177–87.
23. Amado JM, Matos ME, Abreu AM et al. The prevalence of acne in the north of Portugal. J Eur Acad Dermatol Venereol 2006; 20: 1287–95.
24. Sinclair W, Jordaan HF. Global Alliance to Improve Outcomes in Acne. Acneguideline S Afr Med J 2005; 95 (11): 881–92.
25. Whitney KM, Ditre CM. Management strategies for acne vulgaris. Clin Cosmet Invest Dermatol 2011; 4: 41–53.
26. Akman A, Durusoy C, Senturk M et al. Treatment of acne with intermittent and conventional isotretinoin: a randomized, controlled multicenter study. Arch Dermatol Res 2007; 299 (10): 467–73.
27. Bérard A, Azoulay L, Koren G et al. Isotretinoin, pregnancies, abortions and birth defects: a population-based perspective. Br J Clin Pharmacol 2007; 63 (2): 196–205.
28. Bowe WP, Logan AC. Clinical implications of lipid peroxidation in acne vulgaris: old wine in new bottles. Lipids Health Dis 2010; 9: 141.
29. Zouboulis CC, Piquero-Martin J. Update and future of systemic acne treatment. Dermatology 2003; 206: 37–53.
30. Keri J, Shiman M. An update on the management of acne vulgaris. Clin Cosmet Invest Dermatol 2009; 2: 105–10.
31. Radtke MA, Schäfer I, Augustin M. Pharmacoeconomy in acne – evaluation of benefit and economics. J Dtsch Dermatol Ges 2010; 8 (Suppl. 1): S105–S114.
32. Center for drug evaluation and research. Appl. No 76-041. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/076041.pdf
33. Стаценко А.В., Белоусова И.Э., Хайрутдинов В.Р и др. Клинический опыт применения изотретиноина в терапии тяжелых форм акне. Эффективная фармакотерапия. 2014; 4: 4–6. / Statsenko A.V., Belousova I.E., Khairutdinov V.R i dr. Klinicheskii opyt primeneniia izotretinoina v terapii tiazhelykh form akne. Effektivnaia farmakoterapiia. 2014; 4: 4–6. [in Russian]
34. Охлопков В.А., Зубарева Е.Ю., Сукач М.С. и др. Оценка клинической эффективности изотретиноина в терапии больных акне. Сonsilium Medicum. Дерматология (Прил.). 2015; 1: 18–22. / Okhlopkov V.A., Zubareva E.Iu., Sukach M.S. i dr. Otsenka klinicheskoi effektivnosti izotretinoina v terapii bol'nykh akne. Sonsilium Medicum. Dermatology (Suppl.). 2015; 1: 18–22. [in Russian]
2. Zouboulis CC, Piquero-Martin J. Update and future of systemic acne treatment. Dermatology 2003; 206 (1): 37–53.
3. Thiboutot D, Gollnick H, Bettoli V et al. Global Alliance to Improve Outcomes in Acne. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol 2009; 60 (Suppl. 5): S1–50. doi: 10.1016/j. jaad.2009.01.019.
4. Gollnick H, Cunliffe W, Berson D et al. Global Alliance to Improve Outcomes in Acne. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2003; 49 (Suppl. 1): S1–37.
5. Perlamutrov Yu.N., Olkhovskaya K.B. Clinical psychological abnormalities in patients with acne and methods of their correction. Klin. dermatologiya i venerologiya. 2012; 4: 70–2. [in Russian]
6. Dreno B, Alirezai M, Auffret N et al. Clinical and psychological correlation in acne: use of the ECLA and CADI scales. Ann Dermatol Venereol 2007; 134 (5): 451–5.
7. Kotova N.V., Suvorova K.N. Iunosheskie akne. M.–Novosibirsk, 2002; s. 3–54. [in Russian]
8. Araviiskaia E.R. Sovremennyi vzgliad na lechenie akne: sostoianie problemy i novye vozmozhnosti. Lech. vrach. 2003; 3: 4–6. [in Russian]
9. Cunliffe WJ. Management and differential of diagnosis acne. Berlin, 2001; 8–16.
10. Layton AM, Dreno B, Gollnick HP, Zouboulis CC. A review of the European Directive for prescribing systemic isotretinoin for acne vulgaris. J Eur Acad Dermatol Venereol 2006; 20 (7): 773–6.
11. Heller EH, Shiffman NJ. Syntheticretinoids in dermatology. Can Med Ass J 1985; 132: 10: 1129–36.
12. Goldsmith LA, Bolognia JL, Callen JP et al. American Academy of Dermatology Consensus Conference on the safe and optimal use of isotretinoin: summary and recommendations. J Am Acad Dermatol 2004; 50 (6): 900–6.
13. Hansen SR, Mikkelsen CS, Kroon S. Systemic treatment of acne. Tidsskr Nor Laegeforen 2011; 131 (2): 133–5.
14. Adaskevich V.P. Akne vul'garnye i rozovye. M: Meditsinskaia kniga – N.Novgorod: NGMA, 2005. [in Russian]
15. Araviiskaia E.A. Sovremennyi vzgliad na lechenie akne: sostoianie problemy i novye vozmozhnosti. Lech. vrach. 2003; 4: 20–5. [in Russian]
16. Masiukova S.A., Akhtiamov S.N. Akne: problema i reshenie. Concilium Medicum. Dermatology (Suppl.). 2002; 5: 217–23. [in Russian]
17. Potekaev N.N., Goriachkina M.V., Belousova T.L. Akne (ugrevaia bolezn'): sovremennyi vzgliad na problemu. Concilium Medicum. Dermatology (Suppl.). 2008; 1: 12–6. [in Russian]
18. Sardana K, Garg VK. Efficacy of low-dose isotretinoin in acne vulgaris. Indian J Dermatol Venereol Leprol 2010; 76 (1): 7–13.
19. Simpson RC, Grindlay DJ, Williams HC. What’s new in acne? An analysis of systematic reviews and clinically significant trials published in 2010–2011. Clin Exp Dermatol 2011; 36 (8): 840–3.
20. Zouboulis CC. Isotretinoinrevisited: pluripotent effects on human sebaceous gland cells. J Invest Dermatol 2006; 126 (10): 2154–6.
21. Ayer J, Burrows N. Acne: more than skin deep. Postgrad Med J 2006; 82 (970): 500–6.
22. Nelson AM, Zhao W, Gilliland KL et al. Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol 2009; 1 (3): 177–87.
23. Amado JM, Matos ME, Abreu AM et al. The prevalence of acne in the north of Portugal. J Eur Acad Dermatol Venereol 2006; 20: 1287–95.
24. Sinclair W, Jordaan HF. Global Alliance to Improve Outcomes in Acne. Acneguideline S Afr Med J 2005; 95 (11): 881–92.
25. Whitney KM, Ditre CM. Management strategies for acne vulgaris. Clin Cosmet Invest Dermatol 2011; 4: 41–53.
26. Akman A, Durusoy C, Senturk M et al. Treatment of acne with intermittent and conventional isotretinoin: a randomized, controlled multicenter study. Arch Dermatol Res 2007; 299 (10): 467–73.
27. Bérard A, Azoulay L, Koren G et al. Isotretinoin, pregnancies, abortions and birth defects: a population-based perspective. Br J Clin Pharmacol 2007; 63 (2): 196–205.
28. Bowe WP, Logan AC. Clinical implications of lipid peroxidation in acne vulgaris: old wine in new bottles. Lipids Health Dis 2010; 9: 141.
29. Zouboulis CC, Piquero-Martin J. Update and future of systemic acne treatment. Dermatology 2003; 206: 37–53.
30. Keri J, Shiman M. An update on the management of acne vulgaris. Clin Cosmet Invest Dermatol 2009; 2: 105–10.
31. Radtke MA, Schäfer I, Augustin M. Pharmacoeconomy in acne – evaluation of benefit and economics. J Dtsch Dermatol Ges 2010; 8 (Suppl. 1): S105–S114.
32. Center for drug evaluation and research. Appl. No 76-041. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/076041.pdf
33. Statsenko A.V., Belousova I.E., Khairutdinov V.R i dr. Klinicheskii opyt primeneniia izotretinoina v terapii tiazhelykh form akne. Effektivnaia farmakoterapiia. 2014; 4: 4–6. [in Russian]
34. Okhlopkov V.A., Zubareva E.Iu., Sukach M.S. i dr. Otsenka klinicheskoi effektivnosti izotretinoina v terapii bol'nykh akne. Sonsilium Medicum. Dermatology (Suppl.). 2015; 1: 18–22. [in Russian]
2. Zouboulis CC, Piquero-Martin J. Update and future of systemic acne treatment. Dermatology 2003; 206 (1): 37–53.
3. Thiboutot D, Gollnick H, Bettoli V et al. Global Alliance to Improve Outcomes in Acne. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol 2009; 60 (Suppl. 5): S1–50. doi: 10.1016/j. jaad.2009.01.019.
4. Gollnick H, Cunliffe W, Berson D et al. Global Alliance to Improve Outcomes in Acne. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2003; 49 (Suppl. 1): S1–37.
5. Перламутров Ю.Н., Ольховская К.Б. Клинико-психологические отклонения у больных акне и методы их коррекции. Клин. дерматология и венерология. 2012; 4: 70–2. / Perlamutrov Yu.N., Olkhovskaya K.B. Clinical psychological abnormalities in patients with acne and methods of their correction. Klin. dermatologiya i venerologiya. 2012; 4: 70–2. [in Russian]
6. Dreno B, Alirezai M, Auffret N et al. Clinical and psychological correlation in acne: use of the ECLA and CADI scales. Ann Dermatol Venereol 2007; 134 (5): 451–5.
7. Котова Н.В., Суворова К.Н. Юношеские акне. М.–Новосибирск, 2002; с. 3–54. / Kotova N.V., Suvorova K.N. Iunosheskie akne. M.–Novosibirsk, 2002; s. 3–54. [in Russian]
8. Аравийская Е.Р. Современный взгляд на лечение акне: состояние проблемы и новые возможности. Леч. врач. 2003; 3: 4–6. / Araviiskaia E.R. Sovremennyi vzgliad na lechenie akne: sostoianie problemy i novye vozmozhnosti. Lech. vrach. 2003; 3: 4–6. [in Russian]
9. Cunliffe WJ. Management and differential of diagnosis acne. Berlin, 2001; 8–16.
10. Layton AM, Dreno B, Gollnick HP, Zouboulis CC. A review of the European Directive for prescribing systemic isotretinoin for acne vulgaris. J Eur Acad Dermatol Venereol 2006; 20 (7): 773–6.
11. Heller EH, Shiffman NJ. Syntheticretinoids in dermatology. Can Med Ass J 1985; 132: 10: 1129–36.
12. Goldsmith LA, Bolognia JL, Callen JP et al. American Academy of Dermatology Consensus Conference on the safe and optimal use of isotretinoin: summary and recommendations. J Am Acad Dermatol 2004; 50 (6): 900–6.
13. Hansen SR, Mikkelsen CS, Kroon S. Systemic treatment of acne. Tidsskr Nor Laegeforen 2011; 131 (2): 133–5.
14. Адаскевич В.П. Акне вульгарные и розовые. М: Медицинская книга – Н.Новгород: НГМА, 2005. / Adaskevich V.P. Akne vul'garnye i rozovye. M: Meditsinskaia kniga – N.Novgorod: NGMA, 2005. [in Russian]
15. Аравийская Е.А. Современный взгляд на лечение акне: состояние проблемы и новые возможности. Леч. врач. 2003; 4: 20–5. / Araviiskaia E.A. Sovremennyi vzgliad na lechenie akne: sostoianie problemy i novye vozmozhnosti. Lech. vrach. 2003; 4: 20–5. [in Russian]
16. Масюкова С.А., Ахтямов С.Н. Акне: проблема и решение. Concilium Medicum. Дерматология (Прил.). 2002; 5: 217–23. / Masiukova S.A., Akhtiamov S.N. Akne: problema i reshenie. Concilium Medicum. Dermatology (Suppl.). 2002; 5: 217–23. [in Russian]
17. Потекаев Н.Н., Горячкина М.В., Белоусова Т.Л. Акне (угревая болезнь): современный взгляд на проблему. Concilium Medicum. Дерматология (Прил.). 2008; 1: 12–6. / Potekaev N.N., Goriachkina M.V., Belousova T.L. Akne (ugrevaia bolezn'): sovremennyi vzgliad na problemu. Concilium Medicum. Dermatology (Suppl.). 2008; 1: 12–6. [in Russian]
18. Sardana K, Garg VK. Efficacy of low-dose isotretinoin in acne vulgaris. Indian J Dermatol Venereol Leprol 2010; 76 (1): 7–13.
19. Simpson RC, Grindlay DJ, Williams HC. What’s new in acne? An analysis of systematic reviews and clinically significant trials published in 2010–2011. Clin Exp Dermatol 2011; 36 (8): 840–3.
20. Zouboulis CC. Isotretinoinrevisited: pluripotent effects on human sebaceous gland cells. J Invest Dermatol 2006; 126 (10): 2154–6.
21. Ayer J, Burrows N. Acne: more than skin deep. Postgrad Med J 2006; 82 (970): 500–6.
22. Nelson AM, Zhao W, Gilliland KL et al. Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol 2009; 1 (3): 177–87.
23. Amado JM, Matos ME, Abreu AM et al. The prevalence of acne in the north of Portugal. J Eur Acad Dermatol Venereol 2006; 20: 1287–95.
24. Sinclair W, Jordaan HF. Global Alliance to Improve Outcomes in Acne. Acneguideline S Afr Med J 2005; 95 (11): 881–92.
25. Whitney KM, Ditre CM. Management strategies for acne vulgaris. Clin Cosmet Invest Dermatol 2011; 4: 41–53.
26. Akman A, Durusoy C, Senturk M et al. Treatment of acne with intermittent and conventional isotretinoin: a randomized, controlled multicenter study. Arch Dermatol Res 2007; 299 (10): 467–73.
27. Bérard A, Azoulay L, Koren G et al. Isotretinoin, pregnancies, abortions and birth defects: a population-based perspective. Br J Clin Pharmacol 2007; 63 (2): 196–205.
28. Bowe WP, Logan AC. Clinical implications of lipid peroxidation in acne vulgaris: old wine in new bottles. Lipids Health Dis 2010; 9: 141.
29. Zouboulis CC, Piquero-Martin J. Update and future of systemic acne treatment. Dermatology 2003; 206: 37–53.
30. Keri J, Shiman M. An update on the management of acne vulgaris. Clin Cosmet Invest Dermatol 2009; 2: 105–10.
31. Radtke MA, Schäfer I, Augustin M. Pharmacoeconomy in acne – evaluation of benefit and economics. J Dtsch Dermatol Ges 2010; 8 (Suppl. 1): S105–S114.
32. Center for drug evaluation and research. Appl. No 76-041. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/076041.pdf
33. Стаценко А.В., Белоусова И.Э., Хайрутдинов В.Р и др. Клинический опыт применения изотретиноина в терапии тяжелых форм акне. Эффективная фармакотерапия. 2014; 4: 4–6. / Statsenko A.V., Belousova I.E., Khairutdinov V.R i dr. Klinicheskii opyt primeneniia izotretinoina v terapii tiazhelykh form akne. Effektivnaia farmakoterapiia. 2014; 4: 4–6. [in Russian]
34. Охлопков В.А., Зубарева Е.Ю., Сукач М.С. и др. Оценка клинической эффективности изотретиноина в терапии больных акне. Сonsilium Medicum. Дерматология (Прил.). 2015; 1: 18–22. / Okhlopkov V.A., Zubareva E.Iu., Sukach M.S. i dr. Otsenka klinicheskoi effektivnosti izotretinoina v terapii bol'nykh akne. Sonsilium Medicum. Dermatology (Suppl.). 2015; 1: 18–22. [in Russian]
________________________________________________
2. Zouboulis CC, Piquero-Martin J. Update and future of systemic acne treatment. Dermatology 2003; 206 (1): 37–53.
3. Thiboutot D, Gollnick H, Bettoli V et al. Global Alliance to Improve Outcomes in Acne. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol 2009; 60 (Suppl. 5): S1–50. doi: 10.1016/j. jaad.2009.01.019.
4. Gollnick H, Cunliffe W, Berson D et al. Global Alliance to Improve Outcomes in Acne. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2003; 49 (Suppl. 1): S1–37.
5. Perlamutrov Yu.N., Olkhovskaya K.B. Clinical psychological abnormalities in patients with acne and methods of their correction. Klin. dermatologiya i venerologiya. 2012; 4: 70–2. [in Russian]
6. Dreno B, Alirezai M, Auffret N et al. Clinical and psychological correlation in acne: use of the ECLA and CADI scales. Ann Dermatol Venereol 2007; 134 (5): 451–5.
7. Kotova N.V., Suvorova K.N. Iunosheskie akne. M.–Novosibirsk, 2002; s. 3–54. [in Russian]
8. Araviiskaia E.R. Sovremennyi vzgliad na lechenie akne: sostoianie problemy i novye vozmozhnosti. Lech. vrach. 2003; 3: 4–6. [in Russian]
9. Cunliffe WJ. Management and differential of diagnosis acne. Berlin, 2001; 8–16.
10. Layton AM, Dreno B, Gollnick HP, Zouboulis CC. A review of the European Directive for prescribing systemic isotretinoin for acne vulgaris. J Eur Acad Dermatol Venereol 2006; 20 (7): 773–6.
11. Heller EH, Shiffman NJ. Syntheticretinoids in dermatology. Can Med Ass J 1985; 132: 10: 1129–36.
12. Goldsmith LA, Bolognia JL, Callen JP et al. American Academy of Dermatology Consensus Conference on the safe and optimal use of isotretinoin: summary and recommendations. J Am Acad Dermatol 2004; 50 (6): 900–6.
13. Hansen SR, Mikkelsen CS, Kroon S. Systemic treatment of acne. Tidsskr Nor Laegeforen 2011; 131 (2): 133–5.
14. Adaskevich V.P. Akne vul'garnye i rozovye. M: Meditsinskaia kniga – N.Novgorod: NGMA, 2005. [in Russian]
15. Araviiskaia E.A. Sovremennyi vzgliad na lechenie akne: sostoianie problemy i novye vozmozhnosti. Lech. vrach. 2003; 4: 20–5. [in Russian]
16. Masiukova S.A., Akhtiamov S.N. Akne: problema i reshenie. Concilium Medicum. Dermatology (Suppl.). 2002; 5: 217–23. [in Russian]
17. Potekaev N.N., Goriachkina M.V., Belousova T.L. Akne (ugrevaia bolezn'): sovremennyi vzgliad na problemu. Concilium Medicum. Dermatology (Suppl.). 2008; 1: 12–6. [in Russian]
18. Sardana K, Garg VK. Efficacy of low-dose isotretinoin in acne vulgaris. Indian J Dermatol Venereol Leprol 2010; 76 (1): 7–13.
19. Simpson RC, Grindlay DJ, Williams HC. What’s new in acne? An analysis of systematic reviews and clinically significant trials published in 2010–2011. Clin Exp Dermatol 2011; 36 (8): 840–3.
20. Zouboulis CC. Isotretinoinrevisited: pluripotent effects on human sebaceous gland cells. J Invest Dermatol 2006; 126 (10): 2154–6.
21. Ayer J, Burrows N. Acne: more than skin deep. Postgrad Med J 2006; 82 (970): 500–6.
22. Nelson AM, Zhao W, Gilliland KL et al. Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol 2009; 1 (3): 177–87.
23. Amado JM, Matos ME, Abreu AM et al. The prevalence of acne in the north of Portugal. J Eur Acad Dermatol Venereol 2006; 20: 1287–95.
24. Sinclair W, Jordaan HF. Global Alliance to Improve Outcomes in Acne. Acneguideline S Afr Med J 2005; 95 (11): 881–92.
25. Whitney KM, Ditre CM. Management strategies for acne vulgaris. Clin Cosmet Invest Dermatol 2011; 4: 41–53.
26. Akman A, Durusoy C, Senturk M et al. Treatment of acne with intermittent and conventional isotretinoin: a randomized, controlled multicenter study. Arch Dermatol Res 2007; 299 (10): 467–73.
27. Bérard A, Azoulay L, Koren G et al. Isotretinoin, pregnancies, abortions and birth defects: a population-based perspective. Br J Clin Pharmacol 2007; 63 (2): 196–205.
28. Bowe WP, Logan AC. Clinical implications of lipid peroxidation in acne vulgaris: old wine in new bottles. Lipids Health Dis 2010; 9: 141.
29. Zouboulis CC, Piquero-Martin J. Update and future of systemic acne treatment. Dermatology 2003; 206: 37–53.
30. Keri J, Shiman M. An update on the management of acne vulgaris. Clin Cosmet Invest Dermatol 2009; 2: 105–10.
31. Radtke MA, Schäfer I, Augustin M. Pharmacoeconomy in acne – evaluation of benefit and economics. J Dtsch Dermatol Ges 2010; 8 (Suppl. 1): S105–S114.
32. Center for drug evaluation and research. Appl. No 76-041. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/076041.pdf
33. Statsenko A.V., Belousova I.E., Khairutdinov V.R i dr. Klinicheskii opyt primeneniia izotretinoina v terapii tiazhelykh form akne. Effektivnaia farmakoterapiia. 2014; 4: 4–6. [in Russian]
34. Okhlopkov V.A., Zubareva E.Iu., Sukach M.S. i dr. Otsenka klinicheskoi effektivnosti izotretinoina v terapii bol'nykh akne. Sonsilium Medicum. Dermatology (Suppl.). 2015; 1: 18–22. [in Russian]
Авторы
С.А.Масюкова*, Э.Г.Санакоева
Медицинский институт усовершенствования врачей ФГБОУ ВПО Московский государственный университет пищевых производств. 125080,
Россия, Москва, Волоколамское ш., д. 11
*skin-net@mail.ru
125080, Russian Federation, Moscow, Volokolamskoe sh., d. 11
*skin-net@mail.ru
Медицинский институт усовершенствования врачей ФГБОУ ВПО Московский государственный университет пищевых производств. 125080,
Россия, Москва, Волоколамское ш., д. 11
*skin-net@mail.ru
________________________________________________
125080, Russian Federation, Moscow, Volokolamskoe sh., d. 11
*skin-net@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.